Phosphate is a major intracellular anion in mammals. Hydrogen phopshate is a protonated form of phosphate. In serum, phosphate exists in two forms, dihydrogen phosphate (H2PO4) and its salt, mono-hydrogen phosphate (HPO4). At the physiologic pH of 7.40, the pK of H2PO4 is 6.8 and the ratio of HPO4 to H2PO4 is 4:1. Altered level of phosphate can be an indicator of various disorders, such as chronic renal failure, hypoparathyroidism, familial intermittent hyperphosphatemia, endocrine disorders, hyperthyroidism, acromegaly, juvenile hypogonadism, etc. These disorders may lead to either hyper- or hypophosphatemia, which can be caused by cellular shifts of phosphate. Patients with hypophosphatemia can be treated with dietary phosphate supplements (potassium phosphate, for example).
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | PROCALAMINE Approved UseProcalAmine is indicated for peripheral administration in adults to preserve body protein and improve nitrogen balance in well-nourished, mildly catabolic patients who require short-term parenteral nutrition. Launch Date3.89664014E11 |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Diagnostic | Unknown Approved UseUnknown |
|||
Diagnostic | Unknown Approved UseUnknown |
|||
Primary | SODIUM PHOSPHATES INJECTION Approved UseSodium Phosphates Injection, USP, 3mM P/mL, is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. The concomitant amount of sodium (4 mEq/mL) must be calculated into total electrolyte content of such prepared solutions. |
PubMed
Title | Date | PubMed |
---|---|---|
Diurnal variation in the levels of glucose and related substances in healthy and diabetic subjects during starvation. | 1967 Feb |
|
Determination of inorganic phosphate in serum and saliva using a synthetic receptor. | 2003 Jun 12 |
|
Amperometric biosensor for determining human salivary phosphate. | 2005 Aug 15 |
|
Phosphorus amendment reduces hepatic and renal oxidative stress in mallards ingesting lead-contaminated sediments. | 2006 Jun |
Patents
Sample Use Guides
lose body protein: approximately three liters per day of ProcalAmine will provide a total of 90 grams of amino acids, 390 nonprotein calories and the recommended daily intake of principal intra- and extracellular electrolytes for the stable patient. Therapy can begin with three liters of ProcalAmine on the first day with close monitoring of the patient. As with all intravenous fluid therapy, the goal is to provide adequate water to compensate for insensible, urinary and other losses, and electrolytes for replacement and maintenance. These requirements should be determined frequently and appropriately administered. Additional electrolytes should be administered evenly throughout the day, and irritating medications should be injected at an alternate infusion site. Pediatric Use ProcalAmine is intended for use in adults. Use of ProcalAmine in pediatric patients is governed by the same considerations that affect the use of any amino acid solution in pediatrics. The amount administered is dosed on the basis of grams of amino acids/kg of body weight/day. Two to three g/kg of body weight for infants with adequate calories are generally sufficient to satisfy protein needs and promote positive nitrogen balance. Solutions administered by peripheral vein should not exceed twice normal serum osmolarity (718 mOsmol/L). Venous irritation at an infusion site can be minimized by the selection of a large peripheral vein as well as by slowing the rate of infusion. In pediatric patients, the final solution should not exceed twice normal serum osmolarity (718 mOsmol/L).
nausea: for maximum effectiveness never dilute or drink fluids of any kind immediately before or after taking this product. Adults and children 12 years of age and over: one or two tablespoons; children 2 to under 12: one or two teaspoons; repeat dose every 15 minutes or until distress subsides; do not take more than 5 doses in 1 hour without consulting a doctor.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26018307
37% phosphoric acid, 17% EDTA, 10% citric acid, 2% chlorhexidine (solution and gel), and 5.25% NaOCl were tested their antimicrobial activity was tested against Candida albicans, Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Actinomyces meyeri, Parvimonas micra, Porphyromonas gingivalis, and Prevotella nigrescens according to the agar diffusion method. The cytotoxicity of the irrigants was determined by using the MTT assay. Phosphoric acid presented higher antimicrobial activity compared to the other tested irrigants.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29730
Created by
admin on Wed Jul 05 23:52:34 UTC 2023 , Edited by admin on Wed Jul 05 23:52:34 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1060
Created by
admin on Wed Jul 05 23:52:34 UTC 2023 , Edited by admin on Wed Jul 05 23:52:34 UTC 2023
|
PRIMARY | |||
|
C66545
Created by
admin on Wed Jul 05 23:52:34 UTC 2023 , Edited by admin on Wed Jul 05 23:52:34 UTC 2023
|
PRIMARY | |||
|
C018279
Created by
admin on Wed Jul 05 23:52:34 UTC 2023 , Edited by admin on Wed Jul 05 23:52:34 UTC 2023
|
PRIMARY | |||
|
10140-65-5
Created by
admin on Wed Jul 05 23:52:34 UTC 2023 , Edited by admin on Wed Jul 05 23:52:34 UTC 2023
|
PRIMARY | |||
|
GR686LBA74
Created by
admin on Wed Jul 05 23:52:34 UTC 2023 , Edited by admin on Wed Jul 05 23:52:34 UTC 2023
|
PRIMARY | |||
|
DTXSID0064969
Created by
admin on Wed Jul 05 23:52:34 UTC 2023 , Edited by admin on Wed Jul 05 23:52:34 UTC 2023
|
PRIMARY | |||
|
SUB12491MIG
Created by
admin on Wed Jul 05 23:52:34 UTC 2023 , Edited by admin on Wed Jul 05 23:52:34 UTC 2023
|
PRIMARY | |||
|
DB14502
Created by
admin on Wed Jul 05 23:52:34 UTC 2023 , Edited by admin on Wed Jul 05 23:52:34 UTC 2023
|
PRIMARY | |||
|
GR686LBA74
Created by
admin on Wed Jul 05 23:52:34 UTC 2023 , Edited by admin on Wed Jul 05 23:52:34 UTC 2023
|
PRIMARY | |||
|
34683
Created by
admin on Wed Jul 05 23:52:34 UTC 2023 , Edited by admin on Wed Jul 05 23:52:34 UTC 2023
|
PRIMARY | |||
|
236719
Created by
admin on Wed Jul 05 23:52:34 UTC 2023 , Edited by admin on Wed Jul 05 23:52:34 UTC 2023
|
PRIMARY | RxNorm |
ACTIVE MOIETY
SUBSTANCE RECORD